Popular Pre-Market Trades in US Stocks
SHF, up 7.41% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
IREN is up 3.01% in pre-market. Based on recent key news:
<ol>
<li>
On December 16, IREN faces a funding gap of approximately $2.7 billion, despite receiving $1.94 billion in advance payments from Microsoft to support its growth plans. This news has raised market concerns about its capital structure, leading to stock price fluctuations. Source: Zhitong Finance
</li>
<li>
On December 16, IREN's stock price fell from a year-to-date high of $75.85 to $35, breaking the important support level of $48.40. Technical analysis indicates that the stock price may continue to decline, with a target price of $20. Source: Invezz
</li>
<li>
On December 16, analysts raised their EPS estimate for IREN in 2026 to $1.03, with a target price of $85.50, reflecting market confidence in its future profitability. Source: FactSet AI Infrastructure demand growth, significant capital flow.
</li>
</ol>
Top Gainers in Pre-Market US Stocks
cbdMD, up 45.45% in pre-market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Agape ATP is up 45.11% in pre-market. Based on recent key news:
<ol>
<li>
On December 17, Agape ATP announced it will focus on the diversified development of health and sustainable green energy businesses to provide sustainable equity performance value. This move may enhance investor confidence and drive stock price increases. Source: Benzinga
</li>
<li>
On December 17, Agape ATP's third-quarter revenue fell to $370,590, down from $465,500 in the second quarter, and the loss per share remained at $0.01. Despite weak financial performance, the market's positive response to the company's future strategy may drive the stock price up. Source: Benzinga
</li>
<li>
On December 17, Benzinga's stock ranking showed Agape ATP's price trend is negative across all time frames. Nevertheless, the market's optimistic sentiment regarding the company's strategic adjustments may boost the stock price in the short term. Source: Benzinga Increased attention on health and green energy sectors.
</li>
</ol>
DBV Technologies is up 36.82% in pre-market. Based on recent key news:
<ol>
<li>
On December 16, DBV Technologies announced that its drug VIASKIN for treating peanut allergy in children met its primary endpoint in Phase III trials, causing the stock price to surge nearly 70%. The trial results showed that 46.6% of treated children had a response after twelve months, compared to only 14.8% in the placebo group. The company plans to submit a Biologics License Application in the first half of 2026
Source: MT Newswires
</li>
<li>
On December 17, the FDA previously granted breakthrough therapy designation to VIASKIN, and DBV Technologies expects to submit a biologics license application in the first half of 2026, potentially receiving priority review. Source: WSJ
</li>
<li>
On December 17, ABSA and BS warrants are now exercisable, potentially bringing the company up to €168.2 million in cash inflow. As of September 30, 2025, the company's cash stands at $69.8 million, expected to sustain operations until the third quarter of 2026. Source: RTT News The biotechnology sector has recently performed strongly, with significant capital inflows
</li>
</ol>

SHFS

IREN

SHF pre-market up 7.41%; IREN pre-market up 3.01%; cbdMD pre-market up 45.45%; Agape ATP pre-market up 45.11%; DBV Technologies pre-market up 36.82%

Pre-market hot trades in US stocks: SHF up 7.41% in pre-market; IREN up 3.01% in pre-market